Table 1

Baseline demographic and clinical characteristics

Variable

SC placebo + oral indomethacin

(n = 75)

SC rilonacept + oral indomethacin

(n = 74)

SC rilonacept + oral placebo

(n = 73)


Age, years, mean (SD)

51.3 (10.9)

48.6 (10.0)

51.0 (10.8)

Gender, n (%)

Male

71 (94.7)

71 (95.9)

67 (91.8)

Female

4 (5.3)

3 (4.1)

6 (8.2)

Race, n (%)

White

54 (72.0)

54 (73.0)

60 (82.2)

Black or African American

15 (20.0)

15 (20.3)

11 (15.1)

Asian

5 (6.7)

2 (2.7)

2 (2.7)

Other

1 (1.3)

3 (4.1)

0

BMI, kg/m2, mean (SD)

32.1 (6.3)

33.5 (7.5)

33.7 (6.7)

Pain severity, mean (SD)

Likert scale (0 to 4)

2.6 (0.7)

2.7 (0.7)

2.6 (0.7)

Numerical rating scale (0 to 10)

6.8 (2.2)

6.8 (2.0)

6.5 (2.3)

Duration of disease, years, mean (SD)

8.8 (6.7)

11.0 (7.9)

10.2 (9.9)

Prior number of gout flares per year, mean (SD)

4.8 (5.19)

5.5 (5.26)

5.2 (4.76)

Duration of a typical gout flare, days, mean (SD)

5.8 (3.6)

7.1 (4.2)

6.8 (7.3)

Tophi present, n (%)

10 (13.3)

12 (16.2)

13 (17.8)

Serum uric acid, mg/dL, mean (SD)

7.9 (1.9)

8.2 (2.1)

8.3 (1.7)

Prior medication use, n (%)

Urate-lowering therapy

28 (37.3)

34 (45.9)

27 (37.0)

Analgesics (paracetamol or acetylsalicylic acid)

2 (2.7)

9 (12.2)

7 (9.6)


BMI, body mass index.

Terkeltaub et al. Arthritis Research & Therapy 2013 15:R25   doi:10.1186/ar4159

Open Data